



Atty Dkt No. AR 2863N1  
USSN: 09/801,443  
SEP 11 2002  
RECEIVED  
PATENT  
TECH CENTER 1600/290

1

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on 8/30/02

8/30/02  
Date

Signature

Maria E. Valenzuela  
7/12(NB)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Gupta, et al

Serial No: 09/801,443

Filed: 03/07/2001

For: OXYBUTYNIN THERAPY

Group Art Unit: 1615

Examiner: TRAN, S.

AMENDMENT AFTER FINAL

Best  
9-12-02

AMENDMENT UNDER 37 CFR §1.116

EXPEDITED PROCEDURE--EXAMINING GROUP 1615

Box AF  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Madam:

This paper is responsive to the Final Office Action mailed June 26, 2002, for which a response is initially due September 26, 2002. Reconsideration of the application is requested in view of the following amendments and remarks.

AMENDMENTS

In the claims:

Please amend the claims as follows.

1. (Amended) A sustained release dosage form comprising oxybutynin for use in managing the plasma concentration of oxybutynin and the dry mouth associated

Do Not  
Enter.  
S.T  
9/12/02